Study is designed to assess the safety and tolerability of ceralasertib at increasing doses in combination with other anti-cancer treatment in patients with advanced tumours

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505006-41-00

Acronym

D5330C00004

Enrollment

100

Registered

2023-09-04

Start date

2015-05-11

Completion date

2025-03-18

Last updated

2025-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced solid malignancies, ATM deficiency, Biomarkers, Cancer or Advanced solid malignancies, Pharmacokinetics, QT interval prolongation

None listed

Sex/Gender

All

Age

18 Years to No maximum

France

None listed

Source: EU CTIS · Data processed: Feb 4, 2026